Loading organizations...
Loading organizations...
The API for Diagnostic Test Analysis (COVID-19, FLU, RSV, STD,…
Scanbase was founded in 2022 by Steve Roger (Founder) and Jeffrey Lange (Founder).
Scanbase has raised $500K in total across 1 funding round.
Scanbase makes it easy for medical companies to convert photos of rapid diagnostic tests into results. We do this by providing a simple API that any medical company can access.
Key people at Scanbase.
Scanbase was founded in 2022 by Steve Roger (Founder) and Jeffrey Lange (Founder).
Scanbase has raised $500K in total across 1 funding round.
Scanbase's investors include Innovation Endeavors, Tucker Seed Fund LLC, Y Combinator, David Lieb, Sasha Medvedovsky.
Scanbase is a San Francisco-based healthcare technology company founded in 2022 that offers a computer vision API enabling medical companies to analyze at-home rapid diagnostic test results from smartphone photos. Their API supports over 40 lateral flow tests including COVID-19, flu, RSV, and STDs, delivering immediate, objective, and accurate results to healthcare providers. This technology enhances patient access to diagnostics, streamlines workflows, and improves early disease detection and patient monitoring. Scanbase has raised $2.5M, including backing from Y Combinator (W23), and achieved $3M in revenue in 2024 with a small, focused team[1][3][4][6].
---
Scanbase was founded in 2022 in San Francisco by CEO Jeffrey Lange and CTO Steve Roger. The idea emerged from the need to improve the accuracy and accessibility of at-home diagnostic testing, especially highlighted by the COVID-19 pandemic’s demand for rapid, reliable testing solutions. Early traction came from joining Y Combinator’s Winter 2023 batch, which helped accelerate product development and market entry. The company quickly gained investor interest and built a lean team focused on delivering a scalable API solution for medical companies[1][4][6].
---
---
Scanbase rides the growing trend of digital health transformation, particularly the shift toward at-home diagnostics and telehealth accelerated by the COVID-19 pandemic. The timing is critical as healthcare systems seek scalable, accurate, and remote diagnostic solutions to reduce clinical burden and improve patient outcomes. Market forces such as increasing demand for personalized medicine, AI adoption in healthcare, and regulatory support for digital tools favor Scanbase’s growth. By enabling rapid test digitization, Scanbase influences the broader ecosystem by facilitating data-driven healthcare, improving diagnostic accessibility, and fostering innovation in medical technology[2][3][4][6].
---
Looking ahead, Scanbase is poised to expand its test catalog, enhance AI capabilities, and deepen integrations with telehealth and healthcare providers. Trends such as AI-powered diagnostics, remote patient monitoring, and personalized healthcare will shape its journey. As regulatory frameworks evolve to support digital diagnostics, Scanbase’s influence may grow from a niche API provider to a foundational platform in digital health diagnostics. Continued innovation and strategic partnerships will be key to scaling impact and maintaining competitive advantage in a rapidly evolving healthcare landscape[1][3][6].
Scanbase has raised $500K across 1 funding round. Most recently, it raised $500K Seed in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $500K Seed | Innovation Endeavors, Tucker Seed Fund LLC, Y Combinator, David Lieb, Sasha Medvedovsky |
